Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 2
1998 9
1999 4
2000 8
2001 11
2002 10
2003 6
2004 10
2005 6
2006 8
2007 2
2008 3
2010 3
2013 1
2017 3
2018 1
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 14731166

85 results

Results by year

Filters applied: . Clear all
Page 1
Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team.
Staszewski S, Morales-Ramirez J, Tashima KT, Rachlis A, Skiest D, Stanford J, Stryker R, Johnson P, Labriola DF, Farina D, Manion DJ, Ruiz NM. Staszewski S, et al. N Engl J Med. 1999 Dec 16;341(25):1865-73. doi: 10.1056/NEJM199912163412501. N Engl J Med. 1999. PMID: 10601505 Free article. Clinical Trial.
Higher virological effectiveness of NNRTI-based antiretroviral regimens containing nevirapine or efavirenz compared to a triple NRTI regimen as initial therapy in HIV-1-infected adults.
Pérez-Elías MJ, Moreno A, Moreno S, López D, Antela A, Casado JL, Dronda F, Gutiérrez C, Quereda C, Navas E, Abraira V, Rodríguez MA. Pérez-Elías MJ, et al. HIV Clin Trials. 2005 Nov-Dec;6(6):312-9. doi: 10.1310/B3NK-V5XQ-6VX9-5DEK. HIV Clin Trials. 2005. PMID: 16452065 Clinical Trial.
Different Degrees of Immune Recovery Using Antiretroviral Regimens with Vonavir or Zidovudine/Lamivudine/Efavirenz in HIVPositive Patients Receiving First Line Treatment in Iran.
Sadeghi L, Moallemi S, Tabatabai RA, Esmaeilzadeh A, Ahsani-Nasab S, Ahmadi NE, Bayanolhagh S, Lolaie M, Narouei A, SeyedAlinaghi S, Mohraz M. Sadeghi L, et al. Infect Disord Drug Targets. 2018;18(3):207-213. doi: 10.2174/1871526518666180108104031. Infect Disord Drug Targets. 2018. PMID: 29308748
Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection.
Gulick RM, Ribaudo HJ, Shikuma CM, Lustgarten S, Squires KE, Meyer WA 3rd, Acosta EP, Schackman BR, Pilcher CD, Murphy RL, Maher WE, Witt MD, Reichman RC, Snyder S, Klingman KL, Kuritzkes DR; AIDS Clinical Trials Group Study A5095 Team. Gulick RM, et al. N Engl J Med. 2004 Apr 29;350(18):1850-61. doi: 10.1056/NEJMoa031772. N Engl J Med. 2004. PMID: 15115831 Free article. Clinical Trial.
85 results